Blood purification firm CytoSorbents Q3 revenue misses estimates

Cytosorbents

13/11/2025 21:28

Overview

CytoSorbents Q3 2025 revenue rose 10% yr/yr to $9.5 mln, missing analyst expectations

Adjusted EPS for Q3 2025 beats analyst expectations

Company implements workforce reduction to accelerate cash-flow breakeven to Q1 2026

Outlook

CytoSorbents expects cash-flow breakeven by Q1 2026

Company anticipates FDA decision on DrugSorb-ATR by mid-2026

Result Drivers

DISTRIBUTOR SALES - Record sales in distributor territories and strong direct sales outside Germany drove revenue growth

COST REDUCTION - Workforce and cost reduction program implemented to accelerate cash-flow breakeven to Q1 2026

CREDIT AGREEMENT - Amended credit agreement with Avenue Capital Group strengthens balance sheet with $2.5 mln additional cash

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Revenue
Miss
$9.49 mln
$10 mln (3 Analysts)
Q3 Adjusted EPS
Beat
-$0.04
-$0.05 (3 Analysts)
Q3 EPS
-$0.05
Q3 Product Gross Margin
70.00%


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 1 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Cytosorbents Corp is $4.00, about 84% above its November 12 closing price of $0.64

Press Release: ID:nPn8rmcgKa

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)